In light of the increasing importance that apoE genotype appears to play on the efficacy of AD therapeutics [53] and the vascular related side effects of therapeutic removal of Aβ [54], these data highlight the importance of addressing apoE-associated changes in the aging cerebrovasculature in the design and interpretation of new therapeutics for the treatment strategies of AD and CAA. This evidence concerns the gene APOE and Alzheimer disease.